PAWI-2 overcomes tumor stemness and drug resistance via cell cycle arrest in integrin $\beta_3$-KRAS-dependent pancreatic cancer stem cells

Jiongjia Cheng & John R. Cashman

Today, pancreatic cancer (PC) remains a major health problem in the US. The fact that cancer stem cells (CSCs) become enriched in humans following anti-cancer therapy implicates CSCs as key contributors to tumor dormancy, metastasis, and relapse in PC. A highly validated CSC model (FG $\beta_3$ cells) was used to test a novel compound (PAWI-2) to eradicate CSCs. Compared to parental bulk FG cells, PAWI-2 showed greater potency to inhibit cell viability and self-renewal capacity of FG $\beta_3$ cells. For FG $\beta_3$ cells, dysregulated integrin $\beta_3$-KRAS signaling drives tumor progression. PAWI-2 inhibited $\beta_3$-KRAS signaling independent of KRAS. This is clinically relevant. PAWI-2 targeted the downstream TBK1 phosphorylation cascade that was negatively regulated by optineurin phosphorylation via a feedback mechanism. This was confirmed by TBK1 genetic knockdown or co-treatment with TBK1-specific inhibitor (MRT67307). PAWI-2 also overcame erlotinib (an EGFR inhibitor) resistance in FG $\beta_3$ cells more potently than bortezomib. In the proposed working model, optineurin acts as a key regulator to link inhibition of KRAS signaling and cell cycle arrest (G2/M). The findings show PAWI-2 is a new approach to reverse tumor stemness that resensitizes CSC tumors to drug inhibition.

Pancreatic cancer (PC) remains a major health problem in the US and soon will be the second most common cause of mortality due to cancer. One of the only curable treatment options for PC is surgical resection. However, disease recurrence is still at high risk after surgery and a majority of post-surgical patients develop advanced metastatic disease, thus necessitating chemo- and radiation therapies. Front-line chemotherapies cause serious side effects. A majority of PC patients are often resistant to clinical therapies. Thus, it remains a challenge to develop an efficacious clinically useful PC therapy.

Cancer stem cells (CSCs) are hallmarks of cancer and inherently resistant to medical therapy. CSCs become enriched in humans following chemo- or radiotherapy. This implicates CSCs as key contributors to tumor dormancy, metastasis, and relapse. These functional features of CSCs make CSCs different from bulk tumor cells and enable CSCs to initiate and maintain tumor development from tumor cells present in a malignant tumor.

CSCs were identified and prospectively isolated from a number of solid tumors by using CSC-specific biomarkers. These biomarkers show a distinct cell population with increased renewal capacity and the ability to recapitulate heterogeneity, multi-lineage differentiation and long-term repopulation. One cell surface adhesion molecule (i.e., integrin $\alpha_\beta$) is well-established as a driver of tumor progression due to association with greater incidence of metastasis and drug resistance. This occurs in a variety of cancers. The capability of integrin $\alpha_\beta$ to trigger anchorage-independent cell survival and tumor metastasis shows that integrin $\alpha_\beta$ expression is a biomarker-functional contributor to tumor progression and drug resistance. Human pancreatic cancer stem cells (hPCSCs) reported previously (i.e., FG$\beta_3$ cells) are validated human CSC model that overexpresses integrin $\alpha_\beta$. In FG$\beta_3$ cells, integrin $\alpha_\beta$ recruits Kirsten rat sarcoma viral oncogene homologue GTPase (KRAS) and RAS Like Proto-Oncogene B (RabL) to activate serine/threonine kinase Tank-binding kinase 1 (TBK1, IkB kinase (IKK)-related kinase) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) to trigger
dysregulated KRAS-RalB-NF-κB. This pathway was reported to be a pharmacological target to reverse CSC-like properties or re-sensitize drug resistance for established FGβ3 tumors19–21.

Given the important role of hPCSCs, a novel treatment strategy that targets hPCSCs or their extrinsic and intrinsic regulators could be of significant clinical utility to treat PC. Herein, we report PAWI-2 (Fig. 1A) that kills drug-resistant hPCSCs (i.e., FGβ3 cells) and synergizes erlotinib by targeting optineurin (OPTN)-dependent cell cycle arrest. Development of PAWI-2 as an anti-PC drug candidate addresses an unmet clinical need. PAWI-2 may also improve standard of care for patients because it synergizes eradication of hPCSCs.

**Figure 1.** PAWI-2 overcomes tumor stemness driven by integrin β3 expression. (A) Chemical structure of PAWI-2. (B) Overexpression of integrin β3 in FGβ3 cells (with human β3/pcDNA3.1 vector) compared to parental FG cells (with empty vector). (C) Dose-dependent effect of PAWI-2 on inhibition of cell viability in FG and FGβ3 cells. (D–F) Effect of PAWI-2 on the inhibition of primary and secondary tumor sphere formation in FG and FGβ3 cells; (D) representative tumor sphere images; (E) self-renewal capacity measured by quantifying the number of primary and secondary tumor spheres; (F) bar graph of the half-maximum inhibitory concentrations (IC50s). (G–I) Effect of PAWI-2 on activation of cell apoptosis in FG and FGβ3 cells: (G) dose-dependent and (H) time-dependent activation of caspase-3/7 activity by PAWI-2 determined by Caspase-Glo 3/7 assay; (I) immunoblot analyses of PARP (full length) and cleaved PARP as determined with whole-cell extracts. Concentration of PAWI-2 used were as indicated: 1.2–400 nM in C, G, 20 nM in D, E and 50 nM in H, I; treatment time used was as indicated: 72 hours in C, 24 hours in D–G, 0–48 hours in H and 0–32 hours in I; vehicle control (0.5% DMSO). β-Actin or HSP90 were used as loading controls in B, I. Data were mean ± SD (n = 3) in C, E–H; P-values were estimated by Student t tests in C, E–H (*P < 0.05, **P < 0.01, ***P < 0.001). The full-length blots are presented in Supplementary Fig. S7.
Results

Effect of PAWI-2 on cell viability and self-renewal capacity of FGβ3 cells. FGβ3 cells were generated by stable transfection of fast-growing (FG) human PC cells with human β3/pDNA3.19. FGβ3 cells possessing CSC-like properties have an elevated expression of integrin β3 compared to parental, bulk FG cells (Fig. 1B). PAWI-2 was two-fold more potent to inhibit cell viability (Supplemental Table S1, Fig. 1C) of FGβ3 cells (IC50, 15 nM) compared to FG cells (IC50, 36 nM). FGβ3 cells showed four-fold increased self-renewal capacity (i.e., secondary tumor sphere formation mediated by integrin β3) relative to FG cells (Fig. 1D-F). PAWI-2 (20 nM) inhibited self-renewal capacity two-fold in FGβ3 cells (Fig. 1E). In vitro, PAWI-2 was two-fold more effective to inhibit self-renewal capacity of FGβ3 (IC50, 16 nM) compared to FG cells (IC50, 31 nM) (Fig. 1F; Supplemental Table S1).

Effect of PAWI-2 on induction of mitochondrial-controlled apoptosis. PAWI-2 potently (i.e., 5.9-fold relative to vehicle-control) activated apoptosis (i.e., activation of caspase-3/7, Fig. 1G,H) in FGβ3 cells (EC50, 11 nM, 48 hours). PAWI-2-mediated apoptosis was less apparent in FG cells (EC50, 42 nM; 3.5-fold increase). Selective potency of PAWI-2 was further shown by PARP cleavage. Compared to FG cells, induction of PARP cleavage was more apparent in FGβ3 cells (6.7- vs. 3.2-fold increase, respectively, at 24 hours; Fig. 1I). Similarly, apoptosis induced by PAWI-2 in FG and FGβ3 cells was controlled by ATM-mitochondrial p53-dependent apoptotic signaling. PAWI-2 activated upstream DNA-damage checkpoint via ATR/ATM-kinase activation (Supplemental Fig. S1A) and inhibited cytosolic p53/Bax binding to anti-apoptotic Bcl-XL (Supplemental Fig. S1B). This caused activation of pro-apoptotic p53/Bax and induced mitochondrial cytochrome c release to trigger cell apoptosis (Supplemental Fig. S1C). This mechanism of action has been observed for PAWI-2 in other non-CSC cancer cells.22–25.

Effect of PAWI-2 on downstream of the KRAS-NF-κB pathway. In FGβ3 cells, overexpression of integrin αvβ3 interacts with KRAS through galectin-3 to recruit KRAS and RalB to activate TBK1 and NF-κB that triggers dysregulated KRAS-RalB-NF-κB signaling.19–21. This is the dominant mechanism to induce CSC-like properties in FGβ3 cells and causes drug resistance for established FGβ3 tumors. Accordingly, the effect of PAWI-2 on dysregulated integrin αvβ3-KRAS-NF-κB signaling in FGβ3 cells was studied. PAWI-2 neither caused disruption of KRAS interactions with other effectors (i.e., integrin β3, galectin-3; Supplemental Fig. S2A) nor inhibited Ral GTPase (i.e., did not affect RalA/B-GTP, an active form of RalA/B; Supplemental Fig. S2B). PAWI-2 inhibited KRAS-NF-κB phosphorylation of TBK1 at Ser172 (pSer172-TBK1; Fig. 2A) without affecting other key components of this pathway (integrin β3, KRAS, galectin-3, RalB, and c-Raf) were not affected by PAWI-2 up to 5 μM (Supplemental Fig. S2C). PAWI-2 selectively inhibited phosphorylation of TK1. Compared to FG cells (IC50, 92 nM), PAWI-2 inhibited phosphorylation of TBK1 (pSer172-TBK1/TBK1) 5-fold more potently in FGβ3 cells (IC50, 17 nM; Supplemental Fig. S2D), similar to other in vitro cell viability, self-renewal capacity, and cell apoptosis characterization (10–40 nM; Fig. 1F, G; Supplemental Table S1).

Downstream interruption of KRAS-NF-κB signaling (i.e., inhibition of TBK1 with TBK1 shRNA; Fig. 2B–E) largely overcame integrin β3-mediated stemness (i.e., less tumor sphere formation in FGβ3 cells with TBK1 knockdown; Fig. 2D). Treatment with PAWI-2 (10–20 nM) enhanced inhibition of TBK1 knockdown on cell viability (20% greater) and self-renewal capacity (44% greater) in FGβ3 cells (Fig. 2C, D). TBK1 can phosphorylate p62/ sequestosome-1 (p62) at Ser403 and optineurin (OPTN) at Ser17726. However, after treatment with PAWI-2, both phosphorylation of p62 or OPTN were increased 2–5 fold in FG and FGβ3 cells (Fig. 2E). Genetic knockdown of TBK1 down-regulated phosphorylation of p62 but not autophosphorylation of TBK1 or phosphorylation of OPTN (pS172-TBK1 and pS177-OPTN, respectively, Fig. 2E).

Compared to cells treated with PAWI-2 alone, co-treatment with TBK1 kinase inhibitor (MRT67307)27 and PAWI-2 enhanced inhibition of cell viability (30% greater; Supplemental Table S2; Fig. 2F) and self-renewal capacity (25% greater; Fig. 2G) in FG and FGβ3 cells. In FGβ3 cells, enhancement of cell killing with co-treatment with PAWI-2 and MRT67307 was not associated with induction of cell apoptosis. For example, in the presence of PAWI-2 and MRT67307, caspase activation and PARP cleavage was comparable to treatment of PAWI-2 alone (Supplemental Fig. S3A, B). The enhanced inhibition of cell viability and self-renewal capacity (Fig. 2F–G) was associated with OPTN phosphorylation (2–4 fold activation; Supplemental Fig. S3C) similar to the result observed in the genetic knockdown of TBK1 (2–5 fold activation; Fig. 2E). Moreover, pharmaceutical inhibition of TBK1 by MRT67307 also down-regulated phosphorylation of p62 (pS403-p62) but not pS172-TBK1 or pS177-OPTN (Supplemental Fig. S3C). This result showed that phosphorylation of p62 induced by PAWI-2 was most likely related to TBK1 activity but phosphorylation of OPTN may not be solely associated with TBK1 activity.

Effect of PAWI-2 on OPTN phosphorylation in the presence of other inhibitors. Integrin β3-mediated self-renewal capacity is associated with drug resistance in FGβ3 cells.28 Co-administration of erlotinib with proteasome inhibitor bortezomib was examined to determine effects on cell viability (Supplemental Table S2) and self-renewal capacity29. In FGβ3 cells, co-administration of "PAWI-2 and erlotinib" enhanced inhibition of erlotinib alone on cell viability (30% greater) and self-renewal capacity (80% greater), compared to co-administration of "erlotinib and bortezomib" (Fig. 3A, B). Chou-Talalay analysis of synergism or antagonism was calculated based on a dose-dependent inhibition of cell viability for drug alone or drug-drug combinations. Synergism or antagonism between drugs was defined by combination index (CI values), showing PAWI-2 synergized erlotinib (but antagonized bortezomib, CI values > 1; Table 1) with greater synergism for FGβ3 cells compared to FG cells (CI values < 1; Table 1). Synergism between “erlotinib and bortezomib” was observed in FG cells but was less apparent in FGβ3 cells (Table 1). Synergism of “PAWI-2 and erlotinib” paralleled induction of cell apoptosis (i.e., “PAWI-2 and erlotinib” enhanced activation of caspase and PARP cleavage compared to PAWI-2 or erlotinib alone; Supplemental Fig. S4A, B).
Figure 2. PAWI-2 affects KRAS-NF-κB signaling by targeting TBK1 phosphorylation to overcome tumor stemness. (A) Immunoblots and densitometry analysis of phospho-Ser172-TBK1 (pS172-TBK1) and TBK1 as determined with whole-cell extracts. (B–E) TBK1 knockdown enhanced the effect of PAWI-2 in FG and FGβ3 cells: (B) immunoblots show TBK1 genetic knockdown efficiency used in this study; effect of TBK1 knockdown (C) on cell viability inhibited by PAWI-2 as measured by a CellTiter-Glo assay and (D) effects on self-renewal capacity inhibited by PAWI-2 as measured by quantifying the number of secondary tumor spheres; (E) immunoblots and densitometry analysis of the effect of PAWI-2 on pS172-TBK1, TBK1, phospho-Ser403-p62 (pS403-p62), p62, phospho-Ser177-OPTN (pS177-OPTN), OPTN, or NDP52 in cells with TBK1 knockdown compared to control cells. (F,G) Enhancement of inhibition of (F) cell viability and (G) self-renewal capacity by co-treatment of PAWI-2 with TBK1 specific inhibitor (MRT67307, 1µM). Concentrations of PAWI-2 used were as indicated: 50 nM in A, E, 10 nM in C, F and 20 nM in D, G; treatment time used was as indicated: 0–16 hours in A, 24 hours in C, D, F, G and 8 hours in E; vehicle control (0.5% DMSO). GAPDH or HSP90 was used as a loading control in A, B, E. Data are mean ± SD (n = 3) in C, D, F, G; P-values were estimated by Student t tests in C, D, F, G (⁎P < 0.05, ⁎⁎P < 0.01, ⁎⁎⁎P < 0.001). The full-length blots are presented in Supplementary Fig. S7.
Figure 3. (A–C) PAWI-2 overcomes erlotinib resistance in FGβ3 cells. Inhibition of (A) cell viability and (B) self-renewal capacity (secondary tumor sphere formation) by EGFR inhibitor (erlotinib) in the presence of PAWI-2 is significantly enhanced compared to single agent treatment or combination of erlotinib (1 µM) with proteasome inhibitor (bortezomib). (C) Immunoblots and densitometry analysis of the effect on phospho-Ser403-p62 (pS403-p62), p62, phospho-Ser177-OPTN (pS177-OPTN), OPTN, or NDP52 in FG and FGβ3 cells after co-treatment of PAWI-2 with erlotinib or bortezomib. (D) PAWI-2 is more effective than clinically-approved drug combinations of gemcitabine (25 nM) with paclitaxel (25 nM) in FGβ3 cells at inhibiting cell viability; (E) Immunoblots and densitometry analysis of the effect of gemcitabine or paclitaxel or in combination on pS403-p62, pS177-OPTN, OPTN compared to PAWI-2 alone. Concentrations of PAWI-2 used were as indicated: 10 nM in A, 20 nM in B, 50 nM in C–E; concentrations of bortezomib used were as indicated: 10 nM in A, 20 nM in B, 50 nM in C–E; treatment time used was as indicated: 72 hours in A, D, 24 hours in B, 16 hours in C, E; vehicle control (0.5% DMSO). GAPDH was used as a loading control in C, E. Data are mean ± SD (n = 3) in A, B, D; P-values were estimated by Student t tests in A, B, D (**P < 0.01, ***P < 0.001). The full-length blots are presented in Supplementary Fig. S7.
Bortezomib works on inhibition of late stage autophagy that promotes accumulation of p62. However, in our hands, the effect of bortezomib on autophagy alone or in combination with erlotinib in FG and FGβ3 cells was modest (p62 and LC3 accumulation was < 2-fold; Fig. 3C, Supplemental Fig. S4C). The distinct pattern of changes of LC3-I to LC3-II was not significantly affected by co-treatment of PAWI-2 with erlotinib. This showed synergism of PAWI-2 with erlotinib was not dominated by an autophagy-related effect. Synergism between PAWI-2 and erlotinib and antagonism between PAWI-2 with bortezomib were highly correlated with OPTN phosphorylation based on a plot of CI values versus pS177-OPTN fold-change (correlation coefficient $r^2 > 0.8$). Co-administration of erlotinib and PAWI-2 increased pS177-OPTN 4-fold in FGβ3 cells. In contrast, in the presence of PAWI-2 and bortezomib, OPTN phosphorylation was at control value. Similar results were observed for p62 and this can be explained because OPTN acts like a p62-like receptor.

Combination chemotherapy of gemcitabine and nab-paclitaxel has been widely used in the treatment of advanced PC30,31. This drug combination showed comparable inhibition of FG cell viability with PAWI-2 alone (Supplemental Table S3; Fig. 3D). Drug resistance of this combination in FGβ3 cells was not associated with activated apoptosis because a comparable effect (activation of caspase activity and PARP cleavage for the combination compared to gemcitabine or paclitaxel alone) (Supplemental Fig. S5A,B) was observed in both FG and FGβ3 cells. Synergism between gemcitabine and paclitaxel was associated with OPTN phosphorylation (Fig. 3E). OPTN phosphorylation may be linked to microtubule (MT) disturbance because this effect was also observed in paclitaxel (MT stabilizer)-treated cells (Fig. 3E).

Effect of PAWI-2 and MT disturbance agents on cell cycle arrest. PAWI-2 binds tubulin at the same site as colchicine. Changes in pS177-OPTN and acetylation of tubulin (related to MT stabilization) as a function of PAWI-2 treatment in FGβ3 cells was evaluated (Fig. 4A). OPTN phosphorylation was correlated with tubulin acetylation and cell cycle arrest indicators (i.e., 4–6 fold decrease of cyclin D3 and 2–4 fold increase of p21 phosphorylation; Fig. 4A). For comparison, several well-defined MT disrupting agents (including MT stabilizers docetaxel and paclitaxel; MT destabilizers vinblastine and colchicine; Fig. 4B) confirmed this effect. Activation or inhibition of pS177-OPTN closely paralleled increase or inhibition of tubulin acetylation (Fig. 4B). Dose-dependent responses on OPTN phosphorylation or tubulin acetylation (Fig. 4C) by treatment with paclitaxel (activation of pS177-OPTN), PAWI-2 (MT stabilizer or destabilizer, dose-dependent changes on pS177-OPTN) and colchicine (inhibition of pS177-OPTN) was observed. However, inhibition of phosphorylation of TBK1 was only observed for PAWI-2 (Fig. 4B).

Double thymidine block arrests cells at the G1/S boundary and subsequent release to fresh media arrests cells at different boundaries.34,35 Experiments were done to synchronize FGβ3 cells at the G1/S boundary and release upon treatment with vehicle control, PAWI-2 or paclitaxel (Fig. 4D). Activation of pS177-OPTN was detected at later G2/M phase (8 hours after release). This was closely associated with onset of cyclin D3 degradation and also inhibition of TBK1 phosphorylation (Fig. 4D). Similar results were observed for phosphorylation of p62 on Ser403 (pS403-p62). Based on intracellular distribution studies in FGβ3 cells, OPTN and pS177-OPTN (and also p62, NDP52) were mainly found in the cytoplasmic fraction under vehicle control conditions but accumulated in the nucleus with PAWI-2 (Fig. 4E). Accumulation of OPTN in the nuclear fraction was an indicator of G2/M arrest.35 Cellular trafficking mediated by PAWI-2 was also associated with acetylated tubulin localization to nuclei (Fig. 4E). Similarly, nuclear cyclin D3 downregulation and accumulation of p21 (and its phosphorylated form) in G2/M were observed after administration of PAWI-2, paclitaxel or colchicine to FGβ3 cells (Fig. 4F), providing strong evidence that these MT disturbing agents caused FGβ3 cell G2/M arrest. Together, these data show that PAWI-2 induced OPTN phosphorylation was highly associated with cell cycle arrest during mitosis.

Discussion

We have shown that PAWI-2 could reverse cancer stemness and overcome drug resistance in an integrin β3 KRAS-dependent hPCSCs (i.e., FGβ3 cells). A working model of PAWI-2 was proposed (Fig. 5). In this model, OPTN plays a central role in regulation of TBK1 functional activity to reverse tumor stemness and drug resistance in FGβ3 cells. Phosphorylation of conserved OPTN residue (Ser177) by PAWI-2 promotes OPTN translocation.

| Cell lines | Drug/Combo | CI$^a$ values at different ED$^b$<sup>c</sup> |
|-----------|------------|-----------------------------------------------|
|           |            | ED$_{50}$ | ED$_{90}$ | ED$_{95}$ |
| FG        | Erlotinib + Bortezomib | 0.51<sup>d</sup> | 0.56<sup>d</sup> | 0.59<sup>d</sup> |
|           | Erlotinib + PAWI-2 | 0.64<sup>d</sup> | 0.74<sup>d</sup> | 0.86<sup>d</sup> |
|           | Bortezomib + PAWI-2 | 1.56 | 1.50 | 1.47 |
| FGβ3      | Erlotinib + Bortezomib | 0.87<sup>d</sup> | 1.07 | 1.19 |
|           | Erlotinib + PAWI-2 | 0.45<sup>d</sup> | 0.32<sup>d</sup> | 0.25<sup>d</sup> |
|           | Bortezomib + PAWI-2 | 1.55 | 1.59 | 1.63 |

Table 1. Combination index (CI) values quantified synergism after treatment with PAWI-2 and erlotinib or bortezomib in FG and FGβ3 cells. *Ratios of Erlotinib:Bortezomib, Erlotinib:PAWI-2 and Bortezomib:PAWI-2 were 50:1, 50:1 and 1:1, respectively; +Combination Index (CI) values were calculated based on the Chou-Talay method; values of CI < 1, = 1 and > 1 indicate synergism, additive and antagonism, respectively; ED$^{75,90,95}$ represent concentrations that cause 75%, 90% and 95% of proliferation inhibition, respectively; Bold values show synergy.
into the nucleus and causes G2/M arrest. Concomitantly, OPTN phosphorylation induced by PAWI-2 has negative feedback control on TBK1 (dephosphorylation of TBK1 at S172) to inhibit dysregulation of KRAS-NF-κB signaling in FGβ3 cells. This model links a role of OPTN to the functional interplay between G2/M cell cycle arrest and provides a mechanism to explain how PAWI-2 overcomes tumor stemness.

Previously, we showed PAWI-2 activated DNA-damage checkpoint and mitochondrial p53-dependent apoptotic signaling in other non-CSC cancer cells22–24. Data herein showed this was also observed for hPCSCs (FGβ3 cells). For dysregulated KRAS-RalB-NF-κB signaling in FGβ3 cells, galectin-3 plays a critical role in clustering...
intrinsically α3β3 to induce KRAS and enable multiple processes in cancer cells21. In the study herein, PAWI-2 did not disrupt KRAS interactions with other effectors. This differentiates PAWI-2 from other drugs (e.g., GCS-100), that act as galectin-3 inhibitors and pharmacologically disrupt biochemical association between integrin α3β3 and KRAS22. RalA/B serves as molecular regulators of integrin α3β3-KRAS-NF-κB signaling. PAWI-2 also did not measurably affect the inactive/active forms of RalA/B. These findings suggest that PAWI-2 inhibited KRAS-NF-κB signaling regardless of KRAS or Ral status. Given the fact that >90% of KRAS is activated by mutations in PC29 and RAS or Ral inhibitors of these pathways have not proven effective clinically30,31, this suggests that PAWI-2 may possess advantages in clinical applications.

TBK1 is a serine/threonine kinase that is activated by autophosphorylation at Ser172 within the kinase activation loop32. Association of TBK1 with RalB of the major oncogene (RAS) in the integrin α3β3-KRAS-NF-κB signaling pathway promotes tumorigenesis33,34. TBK1 inhibitors (e.g., momelotinib) show limited utility in PC even in combination with other effective PC therapeutics34. As a key kinase in several signaling pathways, TBK1 also phosphorylates p62 or OPTN to enhance their binding capacity with poly-ubiquitin (poly-UB) chains35,36. TBK1 constitutively interacts with OPTN to act as a key modulator to initiate elimination of damaged mitochondria via selective mitophagy (PINK1/Parkin-dependent mitophagy), that is involved in tumor suppression pathways37,38. PAWI-2 was previously reported to affect mitochondrial function (i.e., membrane trafficking, mitochondrial membrane potential changes)39,40. However, in FG3β3 cells neither PINK1 nor Parkin proteins were altered by PAWI-2. This data excludes mitophagy mechanisms initiated via OPTN by PAWI-2. PAWI-2 did not change autophagy biomarker LC3-I to lipidated form LC3-II (Supplemental Fig. S4C). Activation of OPTN phosphorylation by PAWI-2 may be related to other signaling cascades not solely dependent on TBK1. OPTN has also been shown to directly regulate TBK142. A negative feedback control of TBK1 activation by OPTN helps explain the proposed working mechanism of PAWI-2. PAWI-2-induced OPTN phosphorylation negatively regulates TBK1 functional activity (i.e., autophosphorylation inhibited), and causes inhibition of KRAS-NF-κB signaling. This was further shown by exacerbated effects of PAWI-2 on the action of genetic knockdown of TBK1 and pharmacological inhibition (MRT67307) of TBK1 activation. Interestingly, MRT67307 does not affect accumulation of pS172-TBK1 (reversely activated). This shows that in contrast to previous reports27,44, TBK1 activation may not be the sole autacatalytic mechanism responsible operating for MRT67307.

In addition to being a downstream regulator of TBK1 function, OPTN is involved in a variety of other biological functions, including protection against apoptosis, Golgi organization, exocytosis, antiviral innate immune response, selective autophagy and other membrane trafficking mechanisms44,45. OPTN does not have any reported enzymatic activity but usually acts as an adaptor protein that links two different proteins (e.g., TBK1 and PINK1/Parkin)39,41. For tumorigenesis or tumor stemness, OPTN phosphorylation has been largely attributed to regulation of mitophagy44,45 mediated by TBK1, but that was not observed herein for PAWI-2. Phosphorylation of OPTN at Ser177 also plays a pivotal role in mitotic progression and induces OPTN translocation into the nucleus46. OPTN-dependent G2/M cell cycle arrest induced by PAWI-2 in FG3β3 cells parallels this process. Previously, G2/M arrest is independently observed in PAWI-2-treated colon cancer cells46. This regulatory mechanism is abolished at the end of the G2/M phase as a consequence of nuclear translocation of OPTN and leads to increased activity of TBK1 (Supplemental Fig. S6).

Synergism between PAWI-2 and other validated drugs (i.e., erlotinib) was controlled by phosphorylation of OPTN. In contrast, in FG3β3 cells, if antagonism was observed (e.g., PAWI-2 with bortezomib), phosphorylation of OPTN was abolished. This observation helps explain drug resistance observed for FG3β3 cells treated with well-documented PC chemotherapies (e.g., gemcitabine with paclitaxel, Fig. 3E)30,31. OPTN may work as an over-arching branch-point for PAWI-2 inhibition of cell viability to overcome self-renewal capacity in FG3β3 cells and also to synergize other pathway inhibitors (i.e., erlotinib).

In PC cells, PAWI-2 binds to tubulin to stabilize/destabilize microtubules (MTs) and activate apoptotic signaling22-24. Phosphorylation of OPTN was closely associated with MT stabilization because this effect was also observed in cells treated with other MT stabilizers (e.g., paclitaxel or docetaxel; Fig. 4B). OPTN foci distribution

Figure 5. Proposed model depicts a mechanism of PAWI-2 to overcome tumor stemness and drug resistance in FG3β3 cells. Green arrows, stimulation; red lines, inhibition.
is dependent on the integrity of MTs\(^{46-47}\), but no relationship between OPTN phosphorylation and MT disturbance has been reported thus far. Nothing describing synergism between clinically-validated cancer drugs through regulation of OPTN has been reported. Accumulation of pS177-OPTN in the presence of MT stabilizers may be due to the essential role of MTs in coordinating and organizing many crucial cellular steps\(^{48}\). Thus, OPTN phosphorylation induced by PAWI-2 or other MT stabilizers could modulate synergism effects to overcome drug resistance and combat more aggressive CSCs.

In conclusion, PAWI-2 synergized specific pathway inhibitors (e.g., TBK1 inhibitors, EGFR inhibitors) against CSCs. Selective pharmacological potency of PAWI-2 in CSCs (e.g., FG\(_3\) cells versus FG cells) showed the utility of PAWI-2 to inhibit CSCs versus bulk cancer cells. This observation provides a basis for PAWI-2 as an efficient treatment of PC, especially in highly aggressive/metastatic cancer with stem-like properties and intrinsic or acquired drug resistance.

**Methods**

**Cell lines.** FG and FG\(_3\) cells were provided by Dr. David Cheresh (UC San Diego and The Scripps Research Institute). FG\(_3\) cells have been thoroughly documented as an aggressive cell line showing CSC-like properties and cancer drug resistance\(^{19-21}\). FG and FG\(_3\) cells were grown in DMEM with 10% FBS. After thawing, cell lines were cultured at 37 °C in a humidified 5% CO\(_2\) atmosphere and routinely screened for mycoplasma contamination.

**Compounds.** Synthesis and pharmaceutical properties of PAWI-2 (Fig. 1A) were reported previously\(^{25,49}\). Other drugs/inhibitors used in this study are listed in the Supplementary Materials and Methods.

**Cell viability and apoptosis assays.** FG and FG\(_3\) cells were seeded onto plates and treated with test compounds (vehicle, 0.5% DMSO; PAWI-2 or other drugs; 2 to 5000 nM) for 3 days. Cell viability was determined using CellTiter-Glo (Promega). Data were expressed as percentage of survival compared to survival of vehicle-treated cells. A similar protocol was used to test synergy of PAWI-2 in the presence of erlotinib and/or bortezomib. Chou-Talalay analysis used commercial software (CombioSyn)\(^{46}\). Cell apoptosis was determined by quantifying caspase-3/7 activity using Caspase-Glo 3/7 (Promega).

**Tumor-sphere culture and self-renewal assay.** FG and FG\(_3\) cells were seeded on ultra-low attachment plates at single-cell suspensions (1,000 cells ml\(^{-1}\)) in DMEM/F12 medium containing insulin-transferrin-selenium (Corning) supplemented with EGF and bFGF (Gibco). Primary tumor spheres were formed after 7 days. Cells were then treated with test compounds for 24 hours. Primary tumor spheres larger than 50 µm in diameter were counted for each condition in triplicate. Single-cell suspensions were dissociated from primary tumor spheres by filtration through a 40 µm cell strainer and seeded using the same conditions. Secondary tumor spheres were formed after 7 days and treated and counted similarly as that for primary tumor spheres.

**Subcellular fractionation, immunoprecipitation and immunoblotting.** Subcellular fractionation and immunoblot experiments were carried out as before\(^{46}\). Whole-cell extracts were obtained after lysis with RIPA buffer (Supplementary Materials and Methods) and subcellular fractions were obtained after homogenization in isolation buffer and centrifugation. Immunoprecipitation experiments were carried out as before with specific antibodies\(^{46}\). Protein extracts were resolved by SDS-PAGE followed by immunoblotting using antibodies specific for target proteins (Supplementary Materials and Methods). Densities of immunoblot bands were quantified using ImageJ (NIH).

**Genetic knockdown.** FG and FG\(_3\) cells were transfected with TBK1 small hairpin RNA (shRNA; Dharmacon; Supplementary Table S4) using lipofectamine 3000 reagent (Invitrogen). Gene knockdown was confirmed by immunoblotting.

**Ral activation assay.** Affinity pulldown assays for RalA/B were carried out following manufacturer’s instructions (Cell Biolabs). Cells were cultured in suspension and treated with vehicle or PAWI-2 (50 nM) for 8 hours. Lysate obtained was incubated with RalBP1 PBD agarose bead slurry at 4 °C for 1 hour with gentle agitation. Activated forms of Ral (GTP bound) bound to beads were collected, washed and resolved by SDS-PAGE followed by immunoblotting using RalA/B antibodies.

**Double thymidine block and release.** FG\(_3\) cells were first incubated with 2 mM thymidine (Sigma) for 18 hours and released into fresh medium for 8 hours. Thymidine treatment was repeated, and a second release was conducted for 0–8 hours by releasing cells for treatment with vehicle, PAWI-2 or paclitaxel. For G1/S boundary, cells were collected at 0 hour. For the G2/M boundary studies, cells were collected at 8 hours for analysis of protein by immunoblotts.

**Statistical analysis.** IC\(_{50}\) and EC\(_{50}\) values were calculated using a nonlinear regression analysis (GraphPad Prism) of the mean and standard deviation (SD) or standard error of the mean (SEM) of at least triplicate samples for each biological assay. Student t tests were used to calculate statistical significance and a P-value < 0.05 was considered significant.
41. Weil, R., Laplantine, E., Curic, S. & Genin, P. Role of Optineurin in the Mitochondrial Dysfunction: Potential Implications in Neurodegenerative Diseases and Cancer. Front. Immunol. 9, 1243, https://doi.org/10.3389/fimmu.2018.01243 (2018).
42. Pourcelot, M. et al. The Golgi apparatus acts as a platform for TBK1 activation after viral RNA sensing. BMC Biol. 14, 69, https://doi.org/10.1186/s12915-016-0292-z (2016).
43. Heo, J. M., Orudereau, A., Paulo, J. A., Rinehart, J. & Harper, J. W. The PINK1-PARKIN Ubiquitylation Pathway Drives a Program of OPTN/NPD52 Recruitment and TBK1 Activation to Promote Mitophagy. Mol. Cell 60, 7–20, https://doi.org/10.1016/j.molcel.2015.08.016 (2015).
44. Liu, K. et al. Mitophagy Controls the Activities of Tumor Suppressor p53 to Regulate Hepatic Cancer Stem Cells. Mol. Cell 68(281-292), e285, https://doi.org/10.1016/j.molcel.2017.09.022 (2017).
45. Liu, Z. et al. Ubiquitylation of autophagy receptor Optineurin by HACE1 activates selective autophagy for tumor suppression. Cancer Cell 26, 106–120, https://doi.org/10.1016/j.ccr.2014.05.015 (2014).
46. Ying, H., Shen, X., Samaraeena, M. & Yue, B. Y. Studies of optineurin, a glaucoma gene: Golgi fragmentation and cell death from overexpression of wild-type and mutant optineurin in two ocular cell types. Am. J. Pathol. 169, 1976–1989, https://doi.org/10.2353/ajpath.2006.060400 (2006).
47. Brouhard, G. J. & Rice, L. M. Microtubule dynamics: an interplay of biochemistry and mechanics. Nat. Rev. Mol. Cell Biol. 19, 451–463, https://doi.org/10.1038/s41580-018-0009-y (2018).
48. Cashman, J. R., Mercola, M., Schade, D. & Tsuda, M. Compounds for inhibition of cancer cell proliferation. Google Patents, US 13/748,770 (2013).
49. Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440–446, https://doi.org/10.1158/0008-5472.CAN-09-1947 (2010).

Acknowledgements
We thank Dr. David Cheresh of the University of California, San Diego and The Scripps Research Institute for FG and FGβ3 cells. This work was supported by Inception Award from California Institute for Regenerative Medicine (CIRM) (DISC1–10583; J.R. Cashman) and by funds from the Human BioMolecular Research Institute. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official view of CIRM or any other agency of the State of California.

Author contributions
J.C. and J.R.C. conceived the study. J.C. conducted and carried out all the cell-based studies, data analysis and statistical analysis. All authors contributed to drafting and revising the manuscript. All authors approved the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-65804-5.

Correspondence and requests for materials should be addressed to J.C.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2020